Welcome to our dedicated page for Synopsys SEC filings (Ticker: SNPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synopsys, Inc. (SNPS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Synopsys common stock is registered on the Nasdaq Global Select Market, and the company regularly uses Form 8-K and other filings to report material events, financial results, and governance changes. These documents are central resources for understanding how Synopsys presents its business segments, strategic actions, and risk factors to investors.
Recent 8-K filings illustrate several themes that may be of interest to shareholders and analysts. One filing reports a restructuring plan approved by the board of directors, which is expected to affect approximately 10% of the workforce as of fiscal 2025 year-end. Synopsys states that this plan is intended to support investment in key growth opportunities and drive business efficiencies following the completion of its acquisition of Ansys, Inc., with substantial completion expected by the end of fiscal year 2027, subject to local requirements.
Other 8-Ks disclose topics such as the departure or appointment of certain officers, reaffirmation of financial targets, and the announcement of quarterly financial results. In its earnings-related filings and press releases, Synopsys reports revenue and net income on both GAAP and non-GAAP bases, provides reconciliations, and explains adjustments related to amortization of acquired intangible assets, stock-based compensation, acquisition and divestiture items, restructuring charges, and tax effects.
Filings also document regulatory and export control developments. For example, Synopsys reported receiving a letter from the U.S. Department of Commerce’s Bureau of Industry and Security rescinding previously imposed export restrictions related to China, and noted that it is working to restore access to affected products while assessing the impact of such restrictions on its business. Forward-looking statements sections in these filings outline risks and uncertainties related to macroeconomic conditions, industry trends, acquisitions, export controls, and other factors.
Through Stock Titan, users can review these SEC documents alongside AI-powered summaries that highlight key items such as restructuring plans, segment disclosures, export control updates, and earnings metrics. This helps readers quickly identify the portions of Synopsys’ 8-Ks, 10-Ks, 10-Qs, and related filings that are most relevant to their analysis of SNPS.
Synopsys Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned and 0% of the class after an internal realignment.
The filing notes an internal Vanguard realignment on January 12, 2026 that caused certain subsidiaries/divisions to report holdings separately; the amendment is signed on March 27, 2026.
Synopsys Inc. Chief Accounting Officer Sudhindra Kankanwadi exercised 793 restricted stock units into an equal number of common shares on March 15, 2026. To cover tax withholding tied to this vesting, 288 common shares were retained by Synopsys at $412.63 per share, as approved by the Compensation Committee. After these routine compensation-related transactions, Kankanwadi directly holds 22,219 shares of Synopsys common stock.
SYNOPSYS INC CFO Shelagh Glaser reported routine equity compensation activity. On March 15, 2026, 793 restricted stock units converted into 793 shares of common stock as an equity award vested. Following this vesting and related entries, she directly held 18,381 shares of Synopsys common stock.
To cover tax withholding obligations from the vesting, 282 shares were retained by the company at a value of $412.63 per share, as approved by the Compensation Committee and limited to the tax liability. This withholding is recorded as a disposition but is not an open-market sale.
Synopsys Inc. president and CEO Ghazi Sassine reported routine equity compensation activity. On March 15, 2026, he exercised 1,322 restricted stock units, each converting into one share of Synopsys common stock.
To cover tax withholding obligations tied to this vesting, 458 shares of common stock were retained by the company at a price of $412.63 per share, with the amount approved by the Compensation Committee and not exceeding the tax liability. Following these transactions, Sassine directly owned 75,020 shares of Synopsys common stock. No remaining derivative equity awards are shown in this filing.
Synopsys executive chair Aart de Geus reported routine equity compensation activity. He exercised 1,763 restricted stock units, which converted into the same number of Synopsys common shares. To cover tax withholding on this vesting, the company retained 630 shares at a price of $412.63 per share, as approved by the Compensation Committee.
After these transactions, de Geus directly holds 120,128 Synopsys shares. He also has indirect ownership of 308,791 shares through a family trust and 14,500 shares through a partnership. The tax-related share retention does not represent an open-market sale.
Synopsys Inc. executive Janet Lee reported equity award activity involving restricted stock units and common shares. On March 3, 2026, 292 restricted stock units were exercised, converting into 292 shares of common stock at a stated price of $0.00 per share.
On the same date, 127 shares of common stock were disposed of at $424.32 per share to cover tax withholding obligations tied to the vesting of the restricted stock unit installment. The company retained these shares, and the compensation committee approved the transaction, with the retained amount not exceeding the related tax liability. After these transactions, Lee directly held 14,471 shares of Synopsys common stock.
Shimer Peter A reported acquisition or exercise transactions in this Form 4 filing.
Synopsys director Peter A. Shimer received equity awards of Synopsys common stock. On February 27, 2026, he was granted 845 shares and a separate grant of 80 shares, both at a stated price of $0.00 per share, reflecting non-cash stock awards.
The 845-share award vests in three equal installments on the dates immediately preceding each of the first three annual stockholder meetings after the grant date, if he continues to serve on the board. The 80-share award vests in full on the date immediately preceding the first annual meeting after the grant date, also requiring continued board service. Both grants are automatic awards under the Synopsys 2017 Non-Employee Directors Equity Incentive Plan.
Synopsys Inc. executive Janet Lee reported routine equity compensation activity involving restricted stock units and common shares. On 2026-03-01, 699 restricted stock units were exercised or converted, resulting in 699 shares of common stock, with no cash exercise price. After this, Lee held 2,796 restricted stock units and 14,610 common shares directly.
On the same date, 304 common shares were disposed of at $414 per share to satisfy tax withholding obligations related to the RSU vesting. According to the disclosure, these shares were retained by the company for tax withholding, the Compensation Committee approved the disposition, and the number of shares used was not more than the related tax liability. Following this tax-withholding transaction, Lee directly held 14,306 common shares.
Synopsys Inc executive chair Aart de Geus reported an acquisition of 28 shares of Synopsys common stock under the Synopsys, Inc. Employee Stock Purchase Plan. The transaction used code "J" for other acquisition or disposition at a price of $351.90 per share, bringing his directly held shares to 118,995.
He also reported indirect ownership of 308,791 shares held by a family trust and 14,500 shares held by a partnership, reflecting additional interests associated with him beyond his direct holdings.
SYNOPSYS INC CFO Shelagh Glaser acquired additional company stock through an employee program. On February 27, 2026, she obtained 28 shares of Synopsys common stock at $351.90 per share under the Synopsys, Inc. Employee Stock Purchase Plan. Following this transaction, her direct holdings totaled 17,870 shares of common stock.